Median Technologies 将来の成長

Future 基準チェック /26

Median Technologiesは、2.9%と20.3%でそれぞれ年率2.9%で利益と収益が成長すると予測される一方、EPSはgrowで4.3%年率。

主要情報

2.9%

収益成長率

4.3%

EPS成長率

Healthcare Services 収益成長	30.0%
収益成長率	20.3%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	08 Nov 2024

今後の成長に関する最新情報

Recent updates

Revenues Tell The Story For Median Technologies SA (EPA:ALMDT) As Its Stock Soars 72%

Aug 30

Slammed 28% Median Technologies SA (EPA:ALMDT) Screens Well Here But There Might Be A Catch

Jun 30

Investors Give Median Technologies SA (EPA:ALMDT) Shares A 28% Hiding

Mar 14

Median Technologies SA (EPA:ALMDT) Looks Just Right With A 26% Price Jump

Jan 03

Newsflash: Median Technologies SA (EPA:ALMDT) Analysts Have Been Trimming Their Revenue Forecasts

Jul 14

Median Technologies SA (EPA:ALMDT) Might Not Be As Mispriced As It Looks After Plunging 46%

May 05

Is Median Technologies (EPA:ALMDT) Using Too Much Debt?

May 07

Announcing: Median Technologies (EPA:ALMDT) Stock Increased An Energizing 254% In The Last Year

Dec 28

業績と収益の成長予測

ENXTPA:ALMDT - アナリストの将来予測と過去の財務データ ( )EUR Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	36	-24	-24	-22	4
12/31/2025	28	-23	-23	-22	4
12/31/2024	24	-24	-22	-22	4
6/30/2024	22	-25	-20	-19	N/A
3/31/2024	23	-24	-21	-20	N/A
12/31/2023	23	-23	-22	-20	N/A
9/30/2023	23	-22	-20	-19	N/A
6/30/2023	23	-21	-19	-18	N/A
3/31/2023	23	-21	-18	-17	N/A
12/31/2022	24	-20	-17	-16	N/A
9/30/2022	24	-19	-16	-15	N/A
6/30/2022	23	-19	-15	-14	N/A
3/31/2022	22	-19	-13	-12	N/A
12/31/2021	21	-19	-11	-10	N/A
9/30/2021	19	-18	-10	-10	N/A
6/30/2021	18	-18	-10	-9	N/A
3/31/2021	16	-15	-8	-7	N/A
12/31/2020	14	-13	-6	-5	N/A
9/30/2020	12	-11	-4	-4	N/A
6/30/2020	11	-8	-3	-2	N/A
3/31/2020	10	-8	-4	-3	N/A
12/31/2019	9	-8	-5	-4	N/A
9/30/2019	8	-9	-8	-7	N/A
6/30/2019	7	-11	-11	-10	N/A
3/31/2019	7	-13	-13	-13	N/A
12/31/2018	6	-15	-16	-16	N/A
9/30/2018	7	-16	-17	-17	N/A
6/30/2018	7	-17	-18	-18	N/A
3/31/2018	7	-17	N/A	-16	N/A
12/31/2017	8	-17	N/A	-14	N/A
9/30/2017	8	-16	N/A	-12	N/A
6/30/2017	7	-14	N/A	-10	N/A
3/31/2017	7	-12	N/A	-9	N/A
12/31/2016	6	-9	N/A	-8	N/A
9/30/2016	6	-8	N/A	-6	N/A
6/30/2016	5	-7	N/A	-5	N/A
3/31/2016	5	-6	N/A	-4	N/A
12/31/2015	4	-6	N/A	-4	N/A
9/30/2015	3	-5	N/A	-4	N/A
6/30/2015	2	-5	N/A	-5	N/A
3/31/2015	2	-5	N/A	-4	N/A
12/31/2014	2	-4	N/A	-3	N/A
9/30/2014	1	-4	N/A	N/A	N/A
6/30/2014	1	-4	N/A	N/A	N/A
3/31/2014	1	-4	N/A	N/A	N/A
12/31/2013	1	-4	N/A	-4	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ALMDT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ALMDT今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ALMDT今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ALMDTの収益 ( 20.3% ) French市場 ( 5.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: ALMDTの収益 ( 20.3% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ALMDTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Median Technologies 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%, revenue upgraded

Price target increased by 25% to €24.40

Price target decreased by 22% to €19.47

Consensus revenue estimates fall by 12%

Recent updates

First half 2024 earnings released: €0.68 loss per share (vs €0.64 loss in 1H 2023)

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Median Technologies to Share Positive Pivotal Data for Eyonis LCS Diagnostic Software as Medical Device at the IASLC 2024 World Conference on Lung Cancer

Revenues Tell The Story For Median Technologies SA (EPA:ALMDT) As Its Stock Soars 72%

Median Technologies Announces Pivotal Reality Study of Its Eyonis™? Lcs Lung Cancer Diagnostic Met All Primary and Secondary Endpoints

Median Technologies SA to Report First Half, 2024 Results on Oct 24, 2024

Slammed 28% Median Technologies SA (EPA:ALMDT) Screens Well Here But There Might Be A Catch

Consensus EPS estimates fall by 15%

New major risk - Financial position

Consensus EPS estimates fall by 20%

Consensus EPS estimates fall by 20%, revenue upgraded

Median Technologies SA, Annual General Meeting, Jun 19, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Investors Give Median Technologies SA (EPA:ALMDT) Shares A 28% Hiding

Price target increased by 25% to €24.40

Median Technologies SA to Report Fiscal Year 2023 Results on Apr 25, 2024

Median Technologies SA (EPA:ALMDT) Looks Just Right With A 26% Price Jump

Price target decreased by 22% to €19.47

Median Technologies's iBiopsy HCC Detection AI Model Developed on the PHELICAR Clinical Data Registry, to Be Presented at the ESMO Congress

Median Technologies Appoints Ben Mcdonald to Its Board of Directors

Median Technologies SA, Annual General Meeting, Oct 10, 2023

Median Technologies SA to Report First Half, 2023 Results on Oct 19, 2023

Consensus revenue estimates fall by 12%

Newsflash: Median Technologies SA (EPA:ALMDT) Analysts Have Been Trimming Their Revenue Forecasts

Median Technologies SA announced that it expects to receive €10 million in funding from Lake Bridge Capital Inc

Price target decreased by 15% to €29.03

Median Technologies SA announced that it expects to receive €10 million in funding from Lake Bridge Capital Inc

New major risk - Financial position

Median Technologies SA, Annual General Meeting, Jun 20, 2023

Median Technologies SA (EPA:ALMDT) Might Not Be As Mispriced As It Looks After Plunging 46%

Full year 2022 earnings released: €1.28 loss per share (vs €1.25 loss in FY 2021)

Forecast to breakeven in 2025

Median Technologies SA to Report Fiscal Year 2022 Results on Apr 20, 2023

No independent directors

First half 2022 earnings released: €0.57 loss per share (vs €0.65 loss in 1H 2021)

Median Technologies Announces Formation of Clinical Advisory Board for Ibiopsy Lung Cancer Screening

Median Technologies SA to Report Q3, 2022 Results on Oct 20, 2022

Consensus EPS estimates fall by 16%

Median Technologies SA Launches Imaging Lab, Spearheading the Integration of iBiopsy® Artificial Intelligence Technologies Into iCRO Imaging Services for Oncology Trials

Median Technologies SA, Annual General Meeting, Jun 14, 2022

Is Median Technologies (EPA:ALMDT) Using Too Much Debt?

Full year 2021 earnings: EPS misses analyst expectations

No independent directors

Full year 2021 earnings: EPS misses analyst expectations

Median Technologies SA Files FDA 513(g) Regulatory Submission for iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device

Median Technologies Announces New Outstanding Performance for Its iBiopsy® Lung Cancer Screening CADx With a Focus on Stage 1 Lung Cancer Characterization

First half 2021 earnings released: €0.65 loss per share (vs €0.39 loss in 1H 2020)

Price target increased to €28.10

Price target increased to €28.10

Median Technologies SA announced that it has received €28.1 million in funding

Full year 2020 earnings released: €1.05 loss per share (vs €0.66 loss in FY 2019)

New 90-day high: €13.50

Median Technologies Appoints Thomas Bonnefont as Chief Operating and Commercial Officer

Median Technologies Sa Unveils New iBiopsy® Clinical Development Plan on Lung Cancer Screening

Median Technologies Inks Major Research Collaboration Agreement With the University of California San Diego

New 90-day high: €9.18

Announcing: Median Technologies (EPA:ALMDT) Stock Increased An Energizing 254% In The Last Year

Median Technologies Announces the Results of Preliminary Retrospective Study on the Evaluation of the Severity of Hepatic Fibrosis in Non-Alcoholic Steatohepatitis

First half earnings released

New 90-day high: €8.98

New 90-day high - €8.38

Median Technologies SA to Report First Half, 2020 Results on Oct 14, 2020

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘